Thousands of questions are online to launch the first full-cycle college entrance examination volunteer fill-in Agent in China, providing free services to all students nationwide.
On June 10th, Qianwen launched the first full-cycle college entrance examination volunteer filling agent in China, providing free volunteer filling and consulting services for candidates nationwide.
On June 10th, Qianwen launched the first full-cycle college entrance examination Agent in China, providing free volunteer application and consultation services to students nationwide. Qianwen's college entrance examination Agent is built on the Qianwen college entrance examination volunteer large model and Quark's 8-year college entrance examination data experience, with three core capabilities: "volunteer calendar", "volunteer report", and "volunteer Q&A".
Zheng Sishou, product manager of the Qianwen division, introduced that more than 10 million students participate in the college entrance examination in China every year. Less than 5% of families hire professional volunteer application counselors for students, while the remaining 95% rely more on their own exploration to complete their volunteer applications.
The iMedia Consulting "2026 China College Entrance Examination Volunteer Application and Employment Prospects Big Data Analysis Report" shows that by 2025, the market size of paid college entrance examination volunteer application in China will reach 1.09 billion yuan, and is expected to increase to 1.22 billion yuan by 2027. Currently, big companies such as Alibaba, Tencent, Baidu, and ByteDance have all launched AI volunteer application services.
Related Articles

Zhongtai (600918.SH) has received approval from the China Securities Regulatory Commission to publicly issue corporate bonds to professional investors.

Changchun High-Tech Industry (000661.SZ): The application for clinical trials of GenSci136 for injection produced domestically has been approved.

Sanofi (SNY.US) suffers another setback in research and development: Rare disease drug Phase III trial halted after failure, new CEO under pressure.
Zhongtai (600918.SH) has received approval from the China Securities Regulatory Commission to publicly issue corporate bonds to professional investors.

Changchun High-Tech Industry (000661.SZ): The application for clinical trials of GenSci136 for injection produced domestically has been approved.

Sanofi (SNY.US) suffers another setback in research and development: Rare disease drug Phase III trial halted after failure, new CEO under pressure.

RECOMMEND





